Mink therapeutics reports fourth quarter & full year 2024 results and highlights business progress

New york, march 18, 2025 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer t (inkt) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. the company will host a conference call and webcast at 8:30 a.m. et.
INKT Ratings Summary
INKT Quant Ranking